SAR 445877
Alternative Names: anti-PD-1/IL-15 bi-functional antibody; anti-PD-1/IL-15 fusion protein; KD-050; mut-1N-IL-15/38B2; SAR-445877Latest Information Update: 09 Jun 2023
At a glance
- Originator Kadmon Corporation
- Developer Sanofi
- Class Antibodies; Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin 15 replacements; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 14 Apr 2023 Pharmacodynamics and adverse events data from preclinical trial in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 29 Nov 2022 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Netherlands and Spain (IV)
- 08 Apr 2022 Pharmacodynamics data from preclinical studies in Cancer presented at 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)